The past 5–10 years have brought in a new era in the care of patients with thyroid cancer,
with the introduction of transformative diagnostic and management options. Several …

Considerable changes have occurred in the management of differentiated thyroid cancer
(DTC) during the past four decades, based on improved knowledge of the biology of DTC …

This ESMO Clinical Practice Guideline provides updated state-of-the-art recommendations
on management of thyroid cancer (diagnosis, treatment and follow-up), compiled by a …

At present, no European recommendations for the management of pediatric thyroid nodules
and differentiated thyroid carcinoma (DTC) exist. Differences in clinical, molecular, and …

Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid
cancer (DTC) should be implemented in line with patients' risk stratification. Although …

The vast majority of thyroid cancers of follicular origin (TC) have a very favourable outcome,
but 5–10% of cases will develop metastatic disease. Around 60–70% of this subset, hence …

Editor's note: SNMMI and the European Association of Nuclear Medicine periodically define
new standards/guidelines for nuclear medicine practice to help advance the science of …

Background: This exploratory study was meant to assess clinical and safety data with a
novel fibroblast activation protein inhibitor-based targeted theranostics as a salvage …

The diagnostic modalities, stratification tools, and treatment options for patients with thyroid
cancer have rapidly evolved since the development of the American Thyroid Association …

Recurrent, metastatic disease represents the most frequent cause of death for patients with
thyroid cancer, and radioactive iodine (RAI) remains a mainstay of therapy for these patients …